WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose...

FRIDAY, Jan. 31, 2025 -- The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or...

WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose...

FRIDAY, Jan. 31, 2025 -- The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or...

WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose...

FDA approves Journavx (suzetrigine), a new opioid designed to reduce addiction and overdose risks.

The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.

The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive.

Food and Drug Administration (FDA) approved a new medication called Journavx (suzetrigine) to treat moderate to severe acute pain in adults. This...

BOSTON--(BUSINESS WIRE)--Jan. 30, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration...